 - Participants must have measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors RECIST version 1.1 in the dose escalation portion of the trial. Participants in the expansion cohort must have measurable disease per RECIST version 1.1 or disease evaluable by assessment of tumor antigens. 